Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With Atopic Dermatitis

Inclusion Criteria: * Subjects of both sexes, between 6 months and 16 years of age, Caucasian, in good health, whose parents/tutors provided a written and signed informed consent for participation in the study shall be enrolled. In particular, as regards parents/tutors: * Both parents/tutors, in case of joint custody, must provide a written and signed informed consent for the participation of the child in the study according to the instructions provided by the investigators; * They must accept to bring the child to the clinical trial facility on predefined visit days according to the instructions provided by the investigators; * They must be willing and be able to follow the trial requirements provided by the investigators. The inclusion criteria provide that: * Symptoms and signs compatible with a clinical diagnosis of Atopic Dermatitis should be present upon enrollment; * The clinical severity of AD should correspond to an EASI ranging between 1.0 and 21.0 and an IGA equal to 2 or 3; * Pruritus severity assessed by means of VAS scale ≥ 4 cm should be referred to the part of the body to be treated, as a requirement for inclusion in the study; * The clinical assessment should envisage for the patient the indication of a moisturizing/emollient treatment as single therapy for AD (in accordance with European Guidelines on AD treatment). Exclusion Criteria: The following items are to be considered as exclusion criteria: * The application of cortisone-based products on the skin to be treated in the 2 weeks prior to treatment; * Ongoing use at baseline of antibiotics and systemic anti-inflammatory drugs for AD in the 2 weeks preceding treatment and during the study (paracetamol is allowed at dosages and indications recommended for use as an antipyretic and analgesic); * Baseline treatment with anti-inflammatory drugs, antihistamines, antitussives and/or inhaled steroids in the 2 previous weeks, retinoids and/or immunosupressants in the previous 6 months. * Use of systemic steroids in the 4 weeks prior to the study. * Intense and prolonged sun exposure in the 30 days preceding the screening. * Severe AD (EASI \> 21) or mild/moderate AD requiring any local and/or systemic treatment comprised in the prohibited treatments included in the exclusion criteria; * Hypersensitivity to the study products. * Acute or chronic skin diseases - except for atopic eczema - which may invalidate clinical assessments or overlap with AD skin picture; * Systemic diseases which may affect the subject's safety or wellbeing or interfere with skin response.